peptide arrays

The firm is working on more assays to help decide which cancer patients are suitable for immunotherapies and hopes to establish a US-based lab in 2023.

The German tools company has used its peptide microarray technology to develop a set of markers that could help with early detection of the disease.

The company recently expanded its collaboration with Sanquin, the Netherlands' central blood bank, to support its diagnostic development activities.